0.849EUR
42.09 MEUR
174.25 MEUR
19.32 M
About SHIN NIPPON BIOMEDICAL LABORATORIES LTD.
Sector
CEO
Ryoichi Nagata
Website
Headquarters
Tokyo
Employees (FY)
1.21 K
Founded
1957
ISIN
JP3379950003
FIGI
BBG000BSTG44
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: Preclinical Business, Clinical Business, Translational Research Business, Medipolis Business, and Others. The Preclinical Business segment verifies the efficacy and safety of new drugs using experimental animals and bacterial cells. The Clinical Business segment provides the support services for clinical trials and related statistical, analytical, and consulting services for all aspects of new drug development. The Translational Research Business segment utilizes drug and device development capabilities to accelerate drug development which leads to out-licensing to pharmaceutical companies. The Medipolis Business segment deals with the property management and geothermal power generation businesses. The Others segment engages in the information collection in Europe, which includes real estate and environmental equipment operations. The company was founded in April 1957 and is headquartered in Tokyo, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange SHIN NIPPON BIOMEDICAL LABORATORIES LTD. stocks are traded under the ticker YB3.
SHIN NIPPON BIOMEDICAL LABORATORIES LTD. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for SHIN NIPPON BIOMEDICAL LABORATORIES LTD. has a max estimate of 21.382 EUR and a min estimate of 17.106 EUR.
YB3 earnings for the last quarter are 0.24 EUR whereas the estimation was 0.17 EUR which accounts for 41.86% surprise. Estimated earnings for the next quarter are 0.26 EUR. See more details about SHIN NIPPON BIOMEDICAL LABORATORIES LTD. earnings.
SHIN NIPPON BIOMEDICAL LABORATORIES LTD. revenue for the last quarter amounts to 38.49 M EUR despite the estimated figure of 42.06 M EUR. In the next quarter revenue is expected to reach 53.00 M EUR.
Yes, you can track SHIN NIPPON BIOMEDICAL LABORATORIES LTD. financials in yearly and quarterly reports right on TradingView.
YB3 net income for the last quarter is 5.32 M EUR, while the quarter before that showed 10.08 M EUR of net income which accounts for −47.25% change. Track more SHIN NIPPON BIOMEDICAL LABORATORIES LTD. financial stats to get the full picture.
SHIN NIPPON BIOMEDICAL LABORATORIES LTD. dividend yield was 1.82% in 2022, and payout ratio reached 34.35%. The year before the numbers were 2.36% and 23.36% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, YB3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SHIN NIPPON BIOMEDICAL LABORATORIES LTD. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 1.21 K employees. See our rating of the largest employees — is SHIN NIPPON BIOMEDICAL LABORATORIES LTD. on this list?
We've gathered analysts' opinions on SHIN NIPPON BIOMEDICAL LABORATORIES LTD. future price: according to them, YB3 price has a max estimate of 21.38 EUR and a min estimate of 17.11 EUR. Read a more detailed SHIN NIPPON BIOMEDICAL LABORATORIES LTD. forecast: see what analysts think of SHIN NIPPON BIOMEDICAL LABORATORIES LTD. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SHIN NIPPON BIOMEDICAL LABORATORIES LTD. EBITDA is 37.13 M EUR, and current EBITDA margin is 27.28%. See more stats in SHIN NIPPON BIOMEDICAL LABORATORIES LTD. financial statements.